Dividend investing is an excellent strategy for (at least) two reasons. Here are two companies that can pull it off: Amgen ...

The licensing pact adds a second so-called "triple agonist" to the Danish drugmaker's portfolio as competition with Lilly and ...

MSD has fleshed out its cardiovascular disease pipeline by licensing an oral Lp (a) inhibitor from China's Jiangsu Hengrui ...

For some Big Pharma companies, sales in China contributed to more than 10 percent of global sales, making China a top market ...

LAKE ZURICH, IL, USA I March 27, 2025 I Fresenius announced that the Biologics License Application (BLA) for the denosumab biosimilars Conexxence® ...

Novo Nordisk is expanding its pipeline of obesity medicines ... a stiff challenge from Lilly and other potential rivals like Amgen, Pfizer, Zealand and Viking Therapeutics. Novo pioneered the ...

A licensing deal with Jiangsu Hengrui Pharmaceuticals puts Merck in a competitive race to develop a medicine that targets a ...

Viking enrolls around 280 participants in the phase II study evaluating the oral version of its obesity drug. Data from this ...

this allowed it to broaden the pipeline beyond those molecules discovered in-house, much as the more traditional pharma companies were doing at this time. By the mid 2000s Amgen was already a giant.

With President Donald Trump expected to levy tariffs on pharmaceuticals manufactured outside the United States, industry ...

Detailed price information for Iovance Biotherapeutics Inc (IOVA-Q) from The Globe and Mail including charting and trades.

Total Revenues in 2024 reached $492 million, representing a 427% increase over prior yearProduct Revenues in 2024 reached $273 million, ...